We have Co-Founder & Chief Scientific Officer at Mydecine Innovations Group, Rob Roscow, stopping by to discuss creating novel therapeutic options for various mental health issues and addictions. Mydecine has government, military, and academic research contracts across numerous countries and is heavily invested in developing a novel molecule pipeline that includes treatments intended for smoking cessation and treatment of PTSD.
Connect with Robb
Connect with Julian
